NASDAQ:APTX - Aptinyx Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $11.67
Forecasted Upside: 233.33 %
Number of Analysts: 9
Breakdown:
1 Sell Ratings
0 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$3.50 As of 06/14/2021 01:00 AM ET

+0.30 (1.20%)

1 month | 3 months | 12 months

Get New Aptinyx Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for APTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$11.67

▲ +233.33% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Aptinyx in the last 3 months. The average price target is $11.67, with a high forecast of $15.00 and a low forecast of $8.00. The average price target represents a 233.33% upside from the last price of $3.50.

Buy

The current consensus among 9 investment analysts is to buy stock in Aptinyx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

12/22/2019

0 strong buy ratings
5 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

3/21/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

6/19/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/17/2020

0 strong buy ratings
8 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

12/16/2020

0 strong buy ratings
8 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

3/16/2021

0 strong buy ratings
8 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

5/15/2021

0 strong buy ratings
8 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

6/14/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/9/2021	HC Wainwright	Reiterated Rating	Buy	$8.00	High	i
1/29/2021	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight		Medium	i
11/19/2020	HC Wainwright	Boost Price Target	Positive ➝ Buy	$7.00 ➝ $8.00	High	i Rating by Ram Selvaraju at HC Wainwright
11/13/2020	SVB Leerink	Lower Price Target	Outperform	$14.00 ➝ $12.00	High	i
10/28/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$9.00 ➝ $12.00	High	i
10/27/2020	Piper Sandler	Initiated Coverage	Overweight	$10.00	Low	i
10/21/2020	Cowen	Reiterated Rating	Buy		Medium	i
10/20/2020	SVB Leerink	Boost Price Target	Outperform	$12.00 ➝ $14.00	Low	i
10/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		Medium	i
10/1/2020	William Blair	Reiterated Rating	Buy		Low	i Rating by M. Minter at William Blair
8/14/2020	BMO Capital Markets	Reiterated Rating	Buy	$13.00	Medium	i
7/1/2020	SunTrust Banks	Initiated Coverage	Buy	$15.00	High	i
6/18/2020	HC Wainwright	Reiterated Rating	Buy	$7.00	High	i Rating by Ram Selvaraju at HC Wainwright
5/7/2020	William Blair	Initiated Coverage	Outperform		Medium	i Rating by M. Minter at William Blair
4/29/2020	HC Wainwright	Initiated Coverage	Buy	$7.00	High	i Rating by R. Selvaraju at HC Wainwright
11/14/2019	Cowen	Reiterated Rating	Buy		High	i
9/12/2019	Wedbush	Initiated Coverage	Outperform	$7.00	High	i Rating by L. Chico at Wedbush
8/13/2019	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight		High	i
6/20/2019	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$12.00	High	i Rating by M. Goodman at SVB Leerink LLC
6/10/2019	Cowen	Reiterated Rating	Buy		High	i
4/30/2019	Cantor Fitzgerald	Reiterated Rating	Buy		Low	i Rating by Charles Duncan at Cantor Fitzgerald
3/22/2019	BMO Capital Markets	Reiterated Rating	Outperform		High	i Rating by Gary Nachman at BMO Capital Markets
3/22/2019	Cantor Fitzgerald	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $12.00	High	i Rating by Charles Duncan at Cantor Fitzgerald
1/18/2019	BMO Capital Markets	Lower Price Target	Outperform	$18.00	Low	i
1/17/2019	SVB Leerink	Lower Price Target	Outperform	$35.00 ➝ $22.00	High	i Rating by G. Porges at SVB Leerink LLC
1/17/2019	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$30.00 ➝ $8.00	High	i
1/16/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$40.00	High	i Rating by C. Duncan at Cantor Fitzgerald
12/3/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$40.00	Low	i Rating by C. Duncan at Cantor Fitzgerald
11/14/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$40.00	High	i Rating by C. Duncan at Cantor Fitzgerald
7/16/2018	SVB Leerink	Initiated Coverage	Outperform	$35.00	Low	i Rating by G. Porges at SVB Leerink LLC
7/16/2018	Cowen	Initiated Coverage	Outperform		High	i
7/16/2018	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$30.00	Low	i
7/16/2018	BMO Capital Markets	Initiated Coverage	Outperform	$32.00	Low	i

(Data available from 6/14/2016 forward)

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Today's Range

Now: $3.50

$3.40

$3.70

50 Day Range

MA: $2.72

$2.39

$3.50

52 Week Range

Now: $3.50

$2.30

$6.47

Volume

3,746,810 shs

Average Volume

835,402 shs

Market Capitalization

$238.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptinyx?

The following sell-side analysts have issued research reports on Aptinyx in the last year: BMO Capital Markets, Cantor Fitzgerald, Cowen Inc, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, SunTrust Banks, Inc., SVB Leerink LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for APTX.

What is the current price target for Aptinyx?

6 Wall Street analysts have set twelve-month price targets for Aptinyx in the last year. Their average twelve-month price target is $11.67, suggesting a possible upside of 241.1%. SunTrust Banks, Inc. has the highest price target set, predicting APTX will reach $15.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Aptinyx in the next year.
View the latest price targets for APTX.

What is the current consensus analyst rating for Aptinyx?

Aptinyx currently has 1 sell rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APTX will outperform the market and that investors should add to their positions of Aptinyx.
View the latest ratings for APTX.

What other companies compete with Aptinyx?

Other companies that are similar to Aptinyx include Enanta Pharmaceuticals, Amphastar Pharmaceuticals, OrganiGram, BioXcel Therapeutics, PyroGenesis Canada, Syndax Pharmaceuticals, Annexon, G1 Therapeutics, Arcturus Therapeutics, ESSA Pharma, Zomedica, Radius Health, Merus, Travere Therapeutics and Epizyme.

How do I contact Aptinyx's investor relations team?

Aptinyx's physical mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company's listed phone number is 847-871-0377 and its investor relations email address is [email protected] The official website for Aptinyx is www.aptinyx.com.